Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma

Inclusion Criteria

• •1. Written Informed Consent provided by patient
• •2. MM, with the following conditions:
• •(CLOSED) \*For patients in the Vanguard cohort\*
• •1\. Treatment naïve disease with BM clinically indicated
• •\*For patients in the RRMM cohort\*
• •1. Relapsed/refractory disease with BM samples clinically indicated
• •2. Within 4-weeks prior to initiation of 2nd-line or later therapy
• •3. Patient's oncologist must be planning to change the patient's next line of treatment to a monotherapy or combination therapy composed exclusively of drugs from the following list: Bortezomib (Velcade), Carfilzomib (Kyprolis), Lenalidomide (Revlimid), Pomalidomide (Pomalyst), Cyclophosphamide (Cytoxan), Dexamethasone, Ixazomib (Ninlaro), Venetoclax (Venclexta), Selinexor (Xpovio)